• François Schiele, Pierre Sabouret, Etienne Puymirat, Kamel Abdennbi, Frédéric Lebeau, Michel Meltz, Serge Kownator, and Denis Angoulvant.
• Department of Cardiology, University Hospital of Besancon, Besancon, France - francois.schiele@univ-fcomte.fr.
• Panminerva Med. 2023 Dec 1; 65 (4): 521526521-526.

AbstractIn patients admitted for acute myocardial infarction (MI), it has been demonstrated that reducing LDL cholesterol (LDL-c) is associated with a reduction in major adverse cardiovascular events. We describe a consensual proposal made by a French group of experts for lipid-lowering therapy at the acute phase of acute myocardial infarction. A group of French experts comprising cardiologists, lipidologists and general practitioners prepared a proposal for a lipid-lowering strategy with a view to optimizing LDL-c levels in patients hospitalized for myocardial infarction. We describe a strategy for the use of statins, ezetimibe and and/or proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors, with a view to reaching target LDL-c levels as early as possible. This approach, which is currently feasible in France, could considerably improve lipid management in patients after ACS, thanks to its simplicity, rapidity and the magnitude of the decrease in LDL-c that it achieves.

14 keywords...

hide…